Infections and Immunology Health Network
- Electronic Pre-Employment Health Assessment (N10) Form Now Available
- Pharmaceutical Benefits Advisory Committee Recommendations Released on Interferon-Free Treatments for Chronic Hepatitis C
The Infections and Immunology Network has recently completed coordinating a project to review and standardise the pre-employment health assessment form (PEHA) N10 for use across all WA Health sites.
The form collects pre-employment occupational safety and health and infection control data from prospective employees. It is now recommended for use as a standardised state-wide pre-employment data collection tool across WA Health.
The development of the form included an extensive consultation process and review by a working group that included representatives from area health services, the Health Corporate Network, PathWest and the Department of Health.
WA Health staff can access the form on HealthPoint.
Pharmaceutical Benefits Advisory Committee Recommendations released on Interferon-Free Treatments for Chronic Hepatitis C
The Pharmaceutical Benefits Advisory Committee (external site) (PBAC) published its findings (external site) on the applications related to all oral interferon-free treatments for Chronic Hepatitis C (CHC) in April 2015. They found that the new treatments for the Hepatitis C virus (HCV) were very effective and listing of these products would offer options for treatment of Genotype 1-6 CHC.
Additionally, the PBAC advised the Commonwealth Minister for Health that:
- there is the high clinical need for all oral interferon-free treatments of CHC to be made available on the Pharmaceutical Benefits Scheme (PBS)
- these treatments would be cost-effective at $15,000 per quality-adjusted life year range and that there was no basis on which to recommend that any one treatment be more expensive than another
- there is a large opportunity cost to health care system. Given this large opportunity cost, the cost of a course of treatment should be set irrespective of the duration, and that other pricing policies be considered
- that the current treatment for CHC, such as peginterferon and ribavirin alone and in combination with telaprevir, boceprevir or simeprevir, are no longer cost-effective at the prices currently listed on the PBS.